In times of volatility, leadership isn’t just tested; it’s exposed. Economic uncertainty, regulatory shifts, and constant change don’t just raise the stakes for organizations; they redefine what teams need from their leaders. What’s required of a senior leader in moments like these looks very different from what’s expected of an individual contributor. Leaders are making high-stakes decisions with incomplete information, while still being asked to keep teams aligned, motivated, and moving forward.

Join us for a timely discussion on what it takes to build resilient organizations amid sustained change. Our panel brings together leaders who have navigated complexity firsthand. Hear directly from CEOs on how to lead through ambiguity, balancing transparency with confidence, managing risk, and sustaining culture when stability isn’t guaranteed. Learn how to adapt an organization rather than react when disruption hits, and move beyond crisis management by building one that can withstand pressure, evolve with intention, and stay grounded through change.

Note: Each ticket includes two drink vouchers and heavy appetizers.
 

Program

5:30 p.m. – 6:00 p.m.  Networking Reception
6:00 p.m. – 7:00 p.m.  Panel Discussion / Q&A
7:00 p.m. – 7:30 p.m.  Closing Remarks / Networking

Speaker Bios

Katherine Andersen, Head of Life Science & Healthcare at HSBC Innovation Banking, Moderator 

Katherine joined HSBC in April 2023 as a US Founding Executive and to lead Life Science & Healthcare for HSBC Innovation Banking. Prior to HSBC, Katherine spent 8 years at SVB Financial Group serving in an Executive leadership position as the US Head of Life Science & Healthcare, including Head of US Healthcare Corporate Banking, Head of US Healthcare Sponsor Finance, Head of US Relationship Banking, and the Executive Sponsor for Institutionally Distributed Leveraged Finance (launched in 2022 alongside SVB Securities). Katherine’s team managed ~4,200 clients in the US and ~$80B in deposits and investments, amounting to a 75% market share. During this time, Katherine also served on the Board of Directors for SPD Silicon Valley Bank, SVB Financial Group’s Joint Venture headquartered in China. Prior to HSBC and SVB, Katherine spent time in various leadership roles over the course of a decade at Wells Fargo. Prior to that, she was in equity derivatives at Merrill Lynch Global Markets & Investment Banking in NYC. She started her career at GE Capital and was thereafter accepted onto GE's Corporate Audit Staff. While she grew up in Virginia and graduated from Virginia Tech with degrees in Economics and Finance, Katherine has been based in Boston since 2006. She has also completed Dartmouth’s Tuck Executive Leadership and Strategic Impact Program, Wells Fargo’s Transformational Leadership Program, the Program on Negotiation at Harvard Law School, and the GE Capital Financial Management Program. She is also a certified Six Sigma Black Belt professional. Katherine serves on the American Cancer Society’s CEOs Against Cancer team, holds a National Board of Directors position for Women In Bio, and serves on the Board of Advisors for Life Science Cares. 

Sulagna Bhattacharya, CEO at Nanoscope Therapeutics

Sulagna is a serial entrepreneur, having co-founded several biotech and biomedical device/diagnostic companies. Before entering the biotechnology world, Ms. Bhattacharya had decades of experience in management consulting at Deloitte and Hitachi Consulting. Her specialties included business intelligence and risk management. She played a key role in seven full life cycle project implementations, including multi-billion-dollar mergers and acquisitions, and later founded a Management Consulting Company. Currently, Ms. Bhattacharya sits on the Board of Directors of the Biotechnology Innovation Organization (BIO) where she serves on the Health Section and the Emerging Companies Governing Boards. She also serves on multiple committees, including the Capital Formation and Corporate Governance Committees. She is also serving as an Entrepreneur-in-Residence at the University of Texas Southwestern Medical School. Sulagna holds B.Tech degrees in electrical, electronics, and communications, as well as an MBA from the Kellogg School of Management, Northwestern University.

Tamar Grossman, CEO at La Jolla Labs

Tamar is the CEO and co-founder of La Jolla Labs, a biotechnology company focused on advancing RNA-based therapeutics to address rare and complex diseases. With a career spanning over two decades, she has developed extensive expertise in RNA therapeutics, gene therapy, and drug delivery modalities, including siRNA, ASO, mRNA, saRNA, and gene editing. Previously, Dr. Grossman served as the Vice President and Global Head of RNA, Gene Therapy, and Delivery at Johnson & Johnson, where she led global teams in delivering RNA-based, gene therapy, and ADC development candidates across therapeutic areas. Prior to her role at Johnson & Johnson, she was the Head of Rare Diseases at Arcturus Therapeutics, where she developed RNA therapeutics for rare and common disease. Earlier in her career, she held leadership positions at Ionis Pharmaceuticals, including Director of Translational Medicine, where she advanced antisense oligonucleotide programs from concept to clinical development. Dr. Grossman earned her PhD in biochemistry from Tel-Aviv University and completed her postdoctoral training at UCSD. Under her leadership, La Jolla Labs has transitioned from a technology-driven company to an RNA therapeutics-focused organization, leveraging AI and machine learning to accelerate drug discovery and address unmet medical needs.

Pricing Information

• Members/Guests: $75
• Non-Members*: $110

*Not a Member? Click here to purchase a WIB membership and gain access to our video library, mentorship opportunities, and more. 

Please read WIB's Code of Conduct and Refund Policy. 

Note: A confirmation email will be sent after registration has been completed. 

Registration Deadline

June 17, 2026